Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Yung-Chih Kuo

Yung-Chih Kuo

National Chung Cheng University Taiwan

Tzong-Rong Ger

Tzong-Rong Ger

Chung Yuan Christian University Taiwan

Chi Hin Cho

Chi Hin Cho

Chinese University of Hong Kong, China Hong Kong

Thomas E. Adrian

Thomas E. Adrian

UAE University UAE

Jiancheng Hu

Jiancheng Hu

Duke-NUS Medical School Singapore

Jinsong Bian

Jinsong Bian

University of Singapore Singapore

Hajime Hirao

Hajime Hirao

City University Hong Kong

S.M.Sivakumar

S.M.Sivakumar

Jazan University Saudi Arabia

Drug Discovery Congress 2017

Sessions/Tracks

ConferenceSeries Ltd is very delighted to invite you all to the "4th Annual Congress on Drug Discovery & Designing" (Drug Discovery Congress) scheduled on July 03-05, 2017 at Bangkok Thailand. ConferenceSeries Ltd organizes a conference series of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Track 1: Anti-Cancer Drug Discovery

Anticancer drug, also called antineoplastic drug, any drug that remains effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include alkylating agents, antimetabolites, natural products, and hormones. In addition, there are a number of drugs that do not fall within those classes but that demonstrate anticancer activity and therefore are used in the treatment of malignant disease. The term chemotherapy frequently is equated with the use of anticancer drugs, although it more accurately refers to the use of chemical compounds to treat disease generally.One of the major drugs that was used clinically in modern medicine for the treatment of cancer was the alkylating agent mechlorethamine, a nitrogen mustard that in the 1940s was create to be effective in treating lymphomas. In 1956 the antimetabolite methotrexate became the first drug to cure a solid tumour.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 2: Chemoinformatics Drug Discovery

Chemoinformatics plays a vital link between imaginary design and in drug design through extraction of information from the data and translate into knowledge. Derivation of information and knowledge is only one aspect of chemoinformatics. The use of consequent knowledge in a design and selection support role is an important part of the drug design cycle. The main processes within drug discovery are lead documentation, where a lead is something that has activity in the low micro molar range, and lead optimization, which is the process of transforming a lead into a drug candidate. Chemo informatics methods can be used proactively to designing and sieve the most appropriate compounds to work within the real world.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 3: Clinical Trials and Regulatory Affairs

Clinical trials are experiments done in clinical research. Such eventual biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interferences, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that certification further study and comparison. Clinical trials generate data on safety and efficacy.

Regulatory affairs is a comparatively new profession which developed from the desire of governments to protect public health by monitoring the safety and efficacy of products in areas including pharmaceuticals, veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and corresponding medicines.

The companies responsible for the discovery, testing, manufacture and marketing of these products also want to ensure that they supply products that are safe and make a worthwhile contribution to public health and welfare.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 4: Perspective in Drug Discovery

It is driven by chemistry but gradually guided by pharmacology and the clinical Sciences, drug research has contributed more to the development of medicine during the past century than any other scientific factor. Improving the science of drug development and instruction is important in fulfilling the public health. The advent of molecular biology and, in particular, of genomic sciences is having a deep conclusion on drug discovery. Emphasis is positioned on the contrast between the academic and industrial research operating environments, which can influence the efficacy of research collaboration between the two communities, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 5: Pharmaceutical Research & Development

In discovery process comprises the early phases of research, which are designed to identify an investigational drug and perform primary tests in the lab. This first stage of the process takes almost three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people.

These advances offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used alongside diagnostics, clinical trial protocols must be modified and enhanced. This may need the use of additional procedures and resources, as well as new or innovative forms of data collection. Moreover, by their very nature, the patient population known to respond to targeted therapies is narrower, which makes patient recruitment more difficult.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 6: CNS Drug Discovery

The universal market for treatments for central nervous system (CNS) disorders was valued at around US dollars 15 billion in 2011, and is set to raise sharply in the years ahead. This is because of a patent increase in the number of persons aged over 65 (the "baby boomer" effect), which will lead to increased demand for more safe and effective medicines for CNS disorders. 1) how to identify and confirm objects for potential CNS drugs; 2) how to assess brain penetration (both in vitro and in vivo); 3) how to develop in silico methodologies to predict blood-brain barrier dispersion; 4) how to estimate therapeutic efficacy (both in vitro and in vivo); 5) how to establish reliable biomarkers to guide decision making; and 6) how to efficiently apply magnetic resonance imaging to CNS drug discovery.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 7: Diabetes and Obesity Drug Discovery

Obesity is a extensive condition that affects older people, and also increasing numbers of young people. Obesity and diabetes are reciprocal. Equal to the Centre for Disease Control, of the people who are identified with type II diabetes, between 80-90% are also identified as obese. Diabetes is an associated disorder characterized by chronic high blood glucose levels due to the body's failure to produce sufficient insulin to regulate   high glucose levels. There are 2 types of diabetes. Type 1 diabetes, which often arise in adolescents, is caused by the body's inability to mark type 2 diabetes, which occurs as a result of the body's failure to react properly to insulin. Links between obesity and type 2 diabetes. It is known that factors of developing various types of diabetes mellitus. For type 2 diabetes, this contains being overweight (having a body mass index - BMI - of 30 or greater). Overweight is increasing the chance to emerging the common type of diabetes, type 2 diabetes.

Current Research:

  • Obesity stresses intestines of individual cells. Respectively, overeating stresses the membranous network privileged of cells called endoplasmic reticulum.
  •  In current research diabetes and obesity rates increased 6% to 57%.
  • Every three seconds, someone is diagnosed with diabetes.
  • 80 to 90% of peoples diagnosed with diabetes associated with obesity.
  • Treatments and Preventions Obesity- Diabetes
  •  Renin-blocking drugs are used to treat prevention of diabetes associated with obesity. These drugs are used to treat diabetes, control blood pressure, may also be used ultimately obesity, and as well as insulin resistance.
  • Possibly eat whole, fresh, and unprocessed foods.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 8: Drug Delivery & Targeting

Targeted drug delivery, occasionally called as smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on Nano medicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be burdened with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to extend, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug through a biological membrane, whereas the targeted release structure releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the rate of the dosages taken by the patient, having a more identical effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the structure is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 9: HIV Drug Discovery & Research

The development of drugs for HIV infection initiated rapidly after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to achieve this disease. Here we review the current treatment opportunities, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we reflect whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the prospective impact of pharmacogenomics and individualized therapy.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 10: Inflammation and Immunology

Inflammation and Immunology: Many drug discovery researchers focus on inflammation and inflammatory diseases. A significant percentage of the world's population suffers from related afflictions such as asthma, Crohn's disease, rheumatoid arthritis, and atherosclerosis. It is moreover well known that inflammatory processes are also activated in a wide variety of diseases, including cancer.

This track is designed to help the challenge of drug discovery by developing new assays for inflammation targets continually. The conference aims to understand the complex chemical and biological processes of inflammation and assist in the successful progression of inflammation and immunology research.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 11: Innovative Drug Discovery and Nanotechnology

Nanotechnology has now initiated to revolutionize medicine. Nanotechnology contains the use of materials with fundamental length scales in the nanometre dimension which demonstrate significantly changed properties associated to micron structured materials. Such materials can include particles, fibers, grain sizes, etc. This session highlighted the advancements nanotechnology is making in medicine in such fields as disease prevention, diagnosis, and treatment including (but not limited to) drug delivery, tissue engineering, implants, sensors, cancer treatment, and toxicity.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 12: Nutraceutical Drug Discovery and Therapy

The R&D drive in the pharmaceutical sector is concentrated on development of new drugs, innovative/indigenous processes for known drugs and development of plant-based drugs through investigation of leads from the traditional systems of medicine. In addition, many nutraceuticals are being consumed in unregulated markets for perceived benefits in health care and improvement of quality of life. Natural pharmaceuticals (Naturaceuticals), nutraceuticals and cosmeceuticals are of excessive importance as a reservoir of chemical diversity aimed at new drug discovery and are explored for antimicrobial, cardiovascular, immunosuppressive and anticancer drugs. Around 80% of all such products are of plant origin; their sales exceeded US$ 65billion in 2003. Examples of plant products and derivative s used by the pharmaceutical industry include paclitaxel, vincristine, vinblastine, artemisinin, camptothecin, podophyllotoxin, etc. The nutraceutical marketplace in Europe is estimated to be US$ 9 billion, while the US marketplace, estimated to be US$ 10–12 billion in 2003, is expanding at a compounded rate of more than 20% per year. The US Congress has powered the rapid growth of nutraceuticals with the passage of the Dietary Supplement Health and Education Act (DSHEA) in 1994.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 13: Recent advances in Spectroscopy and CADD

New mass spectrometry (MS) methods, collectively known as data independent analysis and hyperactive reaction monitoring, have recently emerged. The analysis of peptides generated by proteolytic breakdown of proteins, known as bottom-up proteomics, functions as the basis for many of the protein research undertaken by mass spectrometry (MS) laboratories. Discovery-based or shotgun proteomics hires data-dependent acquisition (DDA). Herein, a hybrid mass spectrometer first performs a survey scan, from which the peptide ions with the intensity above a predefined threshold value, are stochastically selected, isolated and sequenced by product ion scanning. And targeted proteomics, selected environmental Monitoring (ERM), also known as multiple reactions monitoring (MRM), is used to monitor a number of selected precursor-fragment changes of the targeted amino acids. The selection of the SRM transitions is normally calculated on the basis of the data acquired previously by product ion scanning, repository data in the community databases or based on a series of empirical rules predicting the Enzyme structure sites.

New challenges and opportunities for those involved in Computer-Aided Drug Design. These challenges require us to move beyond typical application areas and develop new tools and techniques. This conference will focus on many of the new challenges facing drug design, and seek to set new research directions to address these challenges.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 14: Regenerative Medicine

Regenerative medicine is a division of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or begin normal function". This field holds the promise of engineering damaged tissues and organs via stimulating the body's own repair mechanisms to functionally heal previously permanent tissues or organs. Regenerative medicine refers to a group of biomedical approaches to clinical therapies that may involve the use of stem cells. Examples include the injection of stem cells or progenitor cells obtained through Fixed differentiation (cell therapies); the induction of regeneration by biologically active molecules administered alone or as a secretion by infused cells (immunomodulation therapy); and transplantation of in vitro grown organs and tissues (tissue engineering).

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track 15: Drug Designing

Drug design is a impressive inventive process of new medication on the basis of biological target. It is also known as rational drug design or rational design. That is the development in medical history in order to yield significant therapeutic response. The drug is an organic molecule, when it is predicament to target site it can either inhibit or activate the function of a biomolecule which effects in therapeutic benefit. The drug design involves the design of such molecules that are similar to the bio molecular target site in shape and charge in order to bind to it. Drug design relies on the knowledge of the three dimensional structure of bimolecular targets.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track16: Insilco Drug Discovery

In silico methods can help in classifying drug targets via bioinformatics tools.They can also be used to analyse the target structures for probable binding/ active sites, generate candidate molecules, check for their drug likeness, berth these molecules with the target, rank them according to their binding affinities, further optimize the molecules to improve binding appearances. The use of computers and computational methods permeates all aspects of drug discovery today and forms the core of structure-based drug design. High-performance computing, data management software and internet are facilitating the access of huge amount of data generated and transforming the massive complex biological data into effective knowledge in modern day drug discovery process. The use of complementary experimental and informatics techniques increases the chance of success in many phases of the discovery process, from the identification of novel targets and elucidation of their functions to the discovery and development of lead compounds with desired properties. Computational tools offer the improvement of delivering new drug candidates more quickly and at a lower cost. Major roles of computation in drug discovery are; (1) Effective screening & de novo design, (2) in silico ADME/T prediction and (3) Advanced techniques for determining protein-ligand binding.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

Track17: Proteomics & Bioinformatics

Proteomics, the large-scale analysis of proteins, contributes significantly to our understanding of gene function in the post-genomic era. Proteomics can be divided into three main areas: (1) protein micro-characterization for large-scale documentation of proteins and their post-translational changes; (2) 'differential display' proteomics for comparison of protein levels with potential application in a wide range of diseases; and (3) studies of protein–protein interactions using techniques such as mass spectrometry or the yeast two-hybrid system. Proteomics technologies are under continuous progresses and new technologies are introduced. Nowadays high quantity acquisition of proteome data is possible. The young and rapidly emerging field of bioinformatics in proteomics is presenting new algorithms to handle large and heterogeneous data sets and to improve the knowledge discovery process. Peptide libraries offer a valuable means for providing functional info regarding protein-modifying enzymes and protein interaction domains.Significantly, new computational and biochemical tools have emerged that facilitate identification of interaction associates and substrates for proteins on the basis of their peptide selectivity profiles.

Related Drug Discovery Congress | Pharmaceutical events| Drug Discovery Conferences

8th Global Pharmacovigilance & Drug Safety Summit,  April 17-18, 2017 Bali, Indonesia; 8th World Congress on Toxicology and Pharmacology, April 13-15, 2017 Dubai, UAE; World Heart Congress May 22-24, 2017 Osaka, Japan; 8th Asian Biosimilars Congress, August 14-16, 2017 Osaka, Japan; 9th World Congress on BA/BE Studies and Bio waivers scheduled to be held July 17-19, 2017 at Melbourne, Australia; 9th Annual Congress on Drug Formulation & Drug Design, October 19-21, 2017 Seoul, South Korea; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 9-10, 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Related Associations or Societies:

The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU), Alzheimer's Association Research (AAR)

 

                                                                                      

About Conference

Conference Series Ltd invites all the participants across the globe to attend "4th Annual Congress on Drug Discovery & Designing scheduled on July 03-05, 2017 at Bangkok, Thailand. Which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Drug Discovery Congress focuses on discussing the treatment strategies, risk management and consequences and challenges in drug design and discovery industry. Drug Discovery Congress provides a platform to critically analyse and understand the methods and mechanisms.

Why to attend???

Join your peers around the world focused on learning about Drug Discovery Congress and related advances, This unique international conference will opportunity to reach the largest assemblage of participants from the Pharma community to gather and share their insights and convey recent developments in the field of drug discovery research and current challenges and possibilities in modelling a new drug and breakthroughs in drug development, Generic drug safety, Novel trends and advanced strategies involving bioavailability bioequivalence research. This is a true forum where ideas and discussion is driven by the participants and interaction with peers and others leads to fruitful outcomes

Drug Discovery Congress is a 3-day event offering the Exhibition, at venue to showcase the new and emerging technologies and have wider sessions involving  Keynote presentation, OralYRF ( student presentation), postere-poster presentations. World-renowned speakers and eminent delegates across the globe attending the conference, to share their valuable presentation on the most recent and advanced techniques, developments, and the newest updates are the prominent features of the conference.

Target Audience: 

  • CEOs, CROs, Directors, Managers and research associates in pharmaceutical industry in the drug or device industries (both innovator and generic)
  • Academic and Industrial Scientists Associated with Discovery, Formulation and The Delivery of Drugs
  • Regulatory and Clinical Scientists Involved In Drug Development
  • Researchers, Education providers In Clinical Pharmacy, Pharmacology and Toxicology
  • Students and Postdoctoral Fellows In All Areas of The Pharmaceutical Sciences
  • Government Agencies Involved In Chemical Safety Assessment
  • Medical Practitioners Such As Clinical Pharmacologists, Clinical Toxicologists.

Market Analysis

 

Drug Discovery Informatics Market size was $ 1.6 billion in 2015 and is anticipated to reach around $ 6.5 billion by 2023. High usage of information technology in data analysis and data mining in terms of drug development, progressions in software versions for data aggregation, processing and analysis, data visualization; and increased use for cloud based services are key factors to drive the drug discovery informatics market.

http://www.wdrb.com/story/33711718/drug-discovery-informatics-market-size-to-exceed-65bn-by-2023-global-market-insights-inc

Global drug discovery informatics market size is expected to record considerable progress over the forecast timeframe because of the introduction of novel platforms and related data analysis services obtained from clinical trials. Sequence analysis platforms related services generated the largest revenue share and are estimated to dominate the industry over the forecast period due to their increasing acceptance and introduction of the advanced genetic sequencing of the genome which provides new opportunities in lead identification.  

Global Business Intelligence (GBI) Research finds that the total drug discovery and development market size in the top seven Asian countries was estimated at $11.2 billion in 2015 and is forecast to reach $17.3 billion by the end of 2018.

The drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea.

http://www.medgadget.com/2016/09/drug-discovery-and-development-market-in-asia-outsourcing-rd-processes-to-asian-countries-academic-institutions-and-healthcare-research-organizations.html

Why Bangkok, Thailand?

Bangkok is the capital and most populous city of Thailand. The city has a population of over 8 million, or 12.6 percent of the country's population.

Thailand's pharmaceutical industry is one of the largest and most developed in Southeast Asia, with projections that it will have the eighth largest pharmaceutical market in the Asia Pacific region in 2016. The country's unique universal medical scheme and its position as a hub of regional distribution have formed a highly attractive market. As the Thai population grows, urbanizes, becomes more affluent, ages and is increasingly sedentary, demand for better healthcare will increase. Equally significant, the Thai generic sector is growing, especially in the public sector, where the government has encouraged its use over patented drugs in order to cut costs. For instance, Greater Pharma has recently launched its first generic inhaler drug for the treatment of osteoporosis, making it the first company in Southeast Asia to manufacture successfully a generic version of this drug.

http://www.boi.go.th/tir/issue_content.php?issueid=125;page=42

Pharmaceutical Associations:

American Association of Pharmaceutical Scientists (AAPS)

Association of International Pharmaceutical Manufacturers (AIPM)

The Association of Pharmaceutical Research & Development (APRD)

American Association for Clinical Chemistry (AACC)

Alliance for Nanotechnology in Cancer (NCI)

American Association of Immunologists (AAI)

American Society for Pharmacology and Experimental Therapeutics (ASPET)

Association of Clinical Research Organizations (ACRO)

International Pharmaceutical Manufacturers Group (IPMG) 

Past Conference Report

Drug Discovery 2016

We gratefully thank all our wonderful Speakers, Conference Attendees, Students, Media Partners, and Associations for making Drug Discovery 2016 Conference the best ever!

The 2nd International Conference and Expo on Drug Discovery & Designing, hosted by the Conference Series LLC was held during October 27-29, 2016 at Rome, Italy, based on the theme “Biological Targets for Advances in Drug Discovery and Logical Design of Therapeutic Agents ". Benevolent response and active participation was received from the Organizing Committee Members along with Scientists, Researchers, Students and leaders from various fields of Pharmaceutical sciences and Drug Discovery, who made this event a grand success.

Conference Series LLC expresses its gratitude to the conference Moderator, namely Dr. Chang -Guo Zhan for taking up the responsibility to coordinate during the sessions. We are indebted to your support.

The conference was initiated with the Honourable presence of the Keynote forum. The list includes:

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

•   Perspective in Drug Discovery

•    Biomarkers in Drug Designing

•    Ligand Based Drug Discovery

•    Scaffold Based Drug Discovery

•    Drug Discovery Software’s

•    CNS Drug Discovery

•    GPCRs Drug Discovery

•    Insilico Drug Discovery

•    Chemoinformatics Drug Discovery

•    Proteomics Drug Discovery

•    Computational Chemistry

•    Computer Aided Drug Designing (CADD)

•    fragment Based Drug Discovery

•    Antibiotics Drug Discovery

•    Mass Spectrometry Drug Discovery

•    Drug Designing

•    structured Based Drug Design

•    Screening and Drug Design

•    Drug Delivery Using Nanotechnology

•    Cardiovascular Drug Discovery

•    Biologics

•    Pharmaceutical Research & Development

•    Entrepreneurs Investment Meet

Conference series LLC thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

With the grand success of Drug Discovery-2016, Conference Series LLC take the immense pleasure to announce the “4th Annual congress on Drug Discovery & Designing "to be held during July 03-05, 2017 at Bangkok, Thailand.

For More details visit:http://drug-discovery.pharmaceuticalconferences.com/asiapacific/

 

 


Past Reports  Proceedings  Gallery  

Supported By

Drug Designing Journal of Developing Drugs Journal of Biomarkers in Drug Development Journal of Pharmaceutical Sciences & Emerging Drugs

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

Collaboration

Collaboration

mediapartner

Media Partner

Past Affiliations

Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos